Cargando…
Alternative Splicing in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancer cases, with more than 850,000 new diagnoses per year globally. Recent trends in the United States have shown that liver cancer mortality has continued to increase in both men and women, while 5-year survival remains bel...
Autores principales: | Lee, Seung Eun, Alcedo, Karel P., Kim, Hong Jin, Snider, Natasha T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490524/ https://www.ncbi.nlm.nih.gov/pubmed/32389640 http://dx.doi.org/10.1016/j.jcmgh.2020.04.018 |
Ejemplares similares
-
Alternative splicing events are prognostic in hepatocellular carcinoma
por: Chen, Qi-Feng, et al.
Publicado: (2019) -
Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5′-nucleotidase (CD73)
por: Snider, Natasha T., et al.
Publicado: (2014) -
Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors
por: Jin, Young-Joo, et al.
Publicado: (2019) -
Therapeutic targeting of alternative splicing to inhibit hepatocellular carcinoma metastasis
por: Lee, Yun-Han
Publicado: (2022) -
Tumor‐Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma
por: Alcedo, Karel P., et al.
Publicado: (2019)